Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.60 |
| ▸ | TDP2 | O95551 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 7/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | JAK3 | P52333 | 3/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.43 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.43 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24151036 | 1.00 | KDR (0.60) | KDRTDP2BTKEGFRJAK3 | |
| SCHEMBL3836940 | 0.81 | KDR (0.60) | KDRITKAURKA | |
| SCHEMBL3049982 | 0.77 | KDR (0.54) | KDRTDP2 | |
| SCHEMBL1333256 | 0.75 | KDR (1.00) | KDRITKAURKA | |
| SCHEMBL3043388 | 0.73 | KDR (0.54) | KDRJAK3 | |
| SCHEMBL3840842 | 0.70 | KDR (0.71) | KDRITKAURKA | |
| SCHEMBL29222569 | 0.70 | BTK (0.55) | KDRTDP2BTKEGFRJAK3 | |
| SCHEMBL3046347 | 0.69 | KDR (0.55) | KDR | |
| SCHEMBL3839296 | 0.68 | BRD4 (0.48) | KDRITKAURKA | |
| SCHEMBL3835061 | 0.68 | KDR (0.55) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | KDR 3104/4885TDP2 170/4885BTK 4194/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | KDR 3104/4885TDP2 170/4885BTK 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.